AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 171 min read$NKTR

Zalevsky Jonathan sold $336K of NKTR

Zalevsky Jonathan (Chief R&D Officer) sold 5,538 shares of NEKTAR THERAPEUTICS (NKTR) at $60.71 ($0.34M total) on 2026-06-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Zalevsky Jonathan
Published Jun 17, 2026, 11:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 17, 2026, 11:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$NKTR
Neutral
medium confidence
Mentioned
$NKTR
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NKTRNeutralLow
01

Why it matters

This adds a fresh datapoint on officer selling activity (5,538 shares) but does not introduce new business fundamentals or catalysts.

02

Market read

Traders may monitor for follow-on insider activity, but the filing alone is unlikely to drive a fundamental repricing.

03

What to watch

The article provides only the sale details; it does not include any concurrent insider buys, changes in guidance, or clinical/regulatory updates that would better explain directional risk.

Relevance 3/10Novelty 6/10Timing: after-hours/next-session following the 2026-06-17 Form 4 filing

Background

The article is a SEC Form 4 insider transaction disclosure for NeKTAR Therapeutics (NKTR).

Company-level read

Ticker impact

$NKTRNeutralMedium confidence
Context

NeKTAR Therapeutics disclosed an officer open-market sale: 5,538 shares sold at $60.71 on 2026-06-15 under a 10b5-1 plan.

Expected impact

Likely limited immediate price impact; any reaction would be sentiment/positioning rather than new fundamentals.

Evidence & confidence

The filing is a routine Form 4 for an officer sale with a pre-arranged 10b5-1 plan; no new operating, clinical, or regulatory facts are provided.

Market effects

Sector

Minimal; this is company-specific insider transaction disclosure without sector-wide catalyst.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Even with a 10b5-1 plan, repeated insider selling can coincide with periods of valuation risk or personal liquidity needs, which some traders may still fade.

Key entities

  • public_company
    NKTR

    NeKTAR Therapeutics; subject of the Form 4 insider sale disclosure.

  • insider
    Zalevsky Jonathan

    Chief R&D Officer who sold 5,538 shares under a pre-arranged 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NKTR insider trading history →

Related articles

AUG 31
$NKTRLow

Rezpegaldesleukin Shows Promise in Atopic Dermatitis

Rezpegaldesleukin, a drug developed by Nektar Therapeutics, significantly reduced disease severity in moderate-to-severe atopic dermatitis patients in a phase 2b trial. All doses showed improved EASI scores and secondary endpoints compared to placebo. The treatment increased regulatory T cells and reduced key AD biomarkers, with common side effects including injection-site reactions. The study was funded by Nektar Therapeutics, and some authors have financial ties to the company.

medscape.com2 min
AUG 28
$NKTRMedAI 8/10

Dollar Balance Sheet Faces a Multi

Nektar Therapeutics (NKTR) reported Q2 2026 results showing increased cash and investments ($1.02B) due to equity raises, but still no commercial revenue. Net loss was $40.6M, down slightly from Q2 2025. The company's focus is on advancing its pipeline, particularly REZPEG, with management emphasizing clinical progress over near-term solvency.

news.alphastreet.com3 min
AUG 27
$NKTRMedAI 8/10

Nektar’s (NKTR) Billion-Dollar Balance Sheet Faces A Multi-Year Test

Nektar Therapeutics (NKTR) reported Q2 earnings, highlighting a $1.02B cash balance and Phase 3 trials for rezpegaldesleukin in atopic dermatitis and alopecia areata. The company expects top-line data in mid-2028 and a potential Biologics License Application submission in 2029. NKTR's operating loss widened to $42.3M, with R&D spending expected to increase. The company raised $373.8M in April 2026 to fund operations.

yahoo.com3 min
AUG 21
$NKTRMedAI 8/10

Nektar (NKTR) Q2 2026 Earnings Call Transcript

Nektar Therapeutics reported Q2 2026 earnings with noncash royalty revenue of $10.1M, a net loss of $40.6M, and cash/investments of $1.02B. The company initiated Phase 3 trials for rezpegaldesleukin and updated full-year guidance, including revenue of $40M-$45M and end-of-year cash of $815M-$840M. Management expects a cash runway into Q3 2028, supported by a recent public offering.

fool.com3 min